Stay updated on KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer
Sign up to get notified when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.

Latest updates to the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 on the page.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check45 days agoChange DetectedUpdated site revision from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check74 days agoChange DetectedAdded Revision: v3.4.2 tag and removed the previous government-funding/operating-status notices, while core study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check81 days agoChange DetectedPage updates include a government funding lapse notice indicating NIH Clinical Center status and a Revision: v3.4.1 (replacing v3.4.0); to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check88 days agoChange DetectedAdded a glossary toggle and new footer metadata labels (Results Submitted, Last Update Submitted that Met QC Criteria) and a revision indicator (Revision: v3.4.0). Removed older labels (No Results Posted, Last Update Submitted that met QC Criteria, No FEAR Act data) and the previous revision (v3.3.4).SummaryDifference0.3%

Stay in the know with updates to KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer
Enter your email address, and we'll notify you when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.